|
rs1003623
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
For the rs1003623, the T allele was associated with an increased breast cancer risk among postmenopausal women with odds ratios (ORs) of 1.4 (95% Confidence Intervals (CIs) = 1.0-1.9) for the CT and 1.6 (95% CIs = 1.0-2.4) for the TT, (P for trend = 0.03).
|
17431766 |
2007 |
|
rs10043985
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
In addition, the AC and AC + CC genotypes of TSLP rs10043985 were confirmed to be associated with an increased risk of BC risk in women aged above 48 years, compared with the AA genotype (AC and AC + CC vs. AA: OR = 9.468, CI = 0.493-181.768, p = 0.04537).
|
31210014 |
2019 |
|
rs1004982
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
The risk of breast cancer with (but not without) proliferative fibrocystic conditions was increased among women homozygous for the minor allele of rs1004982 (C), rs28566535 (C), rs936306 (T), and rs4775936 (C) relative to those homozygous for the major allele [age-adjusted odds ratios (95% confidence intervals), 2.19 (1.24-3.85), 2.20 (1.27-3.82), 1.94 (1.13-3.30), and 1.95 (1.07-3.58), respectively].
|
19064562 |
2008 |
|
rs10053538
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Immunohistochemical analysis showed that the expression of TIM-3 protein in the breast cancer tissues was higher in patients carrying the rs10053538 GT+TT genotype than those with GG genotype (P = 0.012).
|
27248321 |
2016 |
|
rs10057194
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Results from the current meta-analysis suggest that the rs2075685 (G>T) and rs6869366 (G>T) polymorphisms of the XRCC4 gene might increase the risk of breast cancer, whereas rs2075685 (G>T) and rs10057194 (A>G) might be protective factors.
|
22994773 |
2012 |
|
rs10077427
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
The association of genotypes and BC was assessed by computing the odds ratio (OR) and 95% confidence intervals (95% CIs) from logistic regression analyses.We found a statistically significant difference between patient and control groups in the POLK rs10077427 genotypic groups, excluding the recessive model.
|
26765445 |
2016 |
|
rs10090154
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
None of the other three single nucleotide polymorphisms, two associated with prostate (rs10090154 and rs7000448) and one with both prostate and colorectal cancers (rs6583267), was associated with breast cancer risk in our study.
|
18349290 |
2008 |
|
rs10109984
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
In multivariable analyses, WRN V114I (rs2230009) significantly modified the association between cumulative occupational breast dose and risk of breast cancer (adjusted for personal diagnostic exposure) (p = 0.04) and BRCA1 D652N (rs4986850), PRKDC IVS15 + 6C > T (rs1231202), PRKDC IVS34 + 39T > C (rs8178097) and PRKDC IVS31 - 634C > A (rs10109984) significantly altered the personal diagnostic radiation exposure-response relationship (adjusted for occupational dose) (p < or = 0.05).
|
17764108 |
2008 |
|
rs1011329790
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Conversely, low TGFβ1 production variants (C29T SNP and GCTG haplotype) were protective against HER2<sup>+</sup> tumors and correlated negatively with prognostic parameters in HER2<sup>+</sup> and TN BCs, while indicating higher proliferation rates in ER/PR<sup>+</sup>HER2<sup>-</sup> tumors.
|
29362917 |
2018 |
|
rs10145182
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
A two SNP combination of rs10145182 in NIN and rs2134808 in the TUBG1 locus (P-interaction = 0.00001), suggested SNPs in mediators of microtubule nucleation from the centrosome contribute to breast cancer.
|
20508983 |
2011 |
|
rs10146997
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Moreover, G allele carriers in rs10146997 of the NRXN3 gene were the youngest patients at onset of breast cancer</span>.
|
21688152 |
2012 |
|
rs10165970
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Study distribution by tumor was as follows: breast cancer (n=15), prostate cancer (n=3), pancreatic cancer (n=2), non-Hodgkin's lymphoma (n=2), glioma (n=1), chronic lymphocytic leukemia (n=1), colorectal cancer (n=1), non-small cell lung cancer (n=1) and ovarian cancer (n=1).We identified 10 single nucleotide polymorphisms (SNPs) significantly associated with cancer risk: NPAS2 rs10165970 (mixed and breast cancer shiftworkers), rs895520 (mixed), rs17024869 (breast) and rs7581886 (breast); CLOCK rs3749474 (breast) and rs11943456 (breast); RORA rs7164773 (breast and breast cancer postmenopausal), rs10519097 (breast); RORB rs7867494 (breast cancer postmenopausal), PER3 rs1012477 (breast cancer subgroups) and assessed the level of quality evidence to be intermediate.
|
28177907 |
2017 |
|
rs10169372
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
In the fine-mapping analysis, five SNPs showed a consistent association with breast cancer risk in both stages: rs10169372 (2q35), rs283720 (8q24.21), rs10515083 (17q23.2/COX11), rs16955329 (17q23.2/COX11), and rs2787487 (17q23.2/COX11).
|
20699374 |
2010 |
|
rs1017105
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
For rs1017105, which is located in the 3'-UTR of CLDN12, significant differences were observed in the recessive model between the pCR and non-pCR patients with luminal-type BC.
|
31157259 |
2019 |
|
rs10175338
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Breast cancer was inversely associated with CYP1A1 rs104C8943 AG + GG genotype (OR = 0.71, 95% CI = 0.50-0.99; vs. AA genotype) and positively associated with CYP1B1 rs10175338 TT genotype (OR = 1.59, 95% CI = 1.12-2.26; vs. GG genotype) and the CYP3A4 rs2242480 CT + TT genotype (OR = 1.25, 95% CI = 1.00-1.56; vs. CC genotype).
|
27956118 |
2017 |
|
rs10204525
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Associations were estimated with odds ratios (ORs) and 95% confidence intervals (95% CIs).For the rs10204525 and rs7421861 polymorphisms, no differences in breast cancer risk were found in any of the genetic models.
|
27227944 |
2016 |
|
rs1020475809
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
We find that a homozygous common missense variant (NQO1(*)2, rs1800566(T), NM_000903.2:c.558C>T) that disables NQO1 strongly predicts poor survival among two independent series of women with breast cancer (P = 0.002, N = 1,005; P = 0.005, N = 1,162), an effect particularly evident after anthracycline-based adjuvant chemotherapy with epirubicin (P = 7.52 x 10(-6)) and in p53-aberrant tumors (P = 6.15 x 10(-5)).
|
18511948 |
2008 |
|
rs10216653
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
In conclusion, our findings demonstrated suggestive associations of AEI polymorphisms with breast cancer risk (MUC16 rs2591592 and SLAMF1 rs1061217) and prognosis (ZNF331 rs8109631 and CHRAC1 rs10216653).© 2016 Wiley Periodicals, Inc.
|
27128794 |
2017 |
|
rs10235235
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
To our knowledge rs10235235 is the first single nucleotide polymorphism to be associated with both breast cancer risk and age at menarche consistent with the well-documented association between later age at menarche and a reduction in breast cancer risk.
|
24887515 |
2014 |
|
rs1024611
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
To that effect, polymorphisms in genes coding for IL-4 (IL-4 C-590T; rs2243250), IFN-γ (IFN-G A + 874T; rs2430561) and MCP-1 (MCP-1 A-2578G; rs1024611) were examined in premenopausal, healthy women (N = 239) and patients with breast cancer (N = 182) from western India.
|
24164868 |
2014 |
|
rs10273424
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
rs10273424, which maps approximately 50 kb centromeric to the cytochrome P450 3A (CYP3A) gene cluster at chromosome 7q22.1, was associated with a 21.8% reduction in E1G levels (95% confidence interval [CI] = 27.8% to 15.3% reduction; P = 2.7 × 10(-9)) and a modest reduction in the risk of breast cancer in case patients who were diagnosed at or before age 50 years (odds ratio [OR] = 0.91, 95% CI = 0.83 to 0.99; P = .03) but not in those diagnosed after age 50 years (OR = 1.01, 95% CI = 0.93 to 1.10; P = .82).
|
22472546 |
2012 |
|
rs1029342144
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
An increase in breast cancer-specific mortality was observed for carriers of the germline MDM2 SNP309 rare GG-genotype (range hazard ratios: 2-3) or TP53 R72P heterozygous GC-genotype (range hazard ratios: 1-2) compared to those having the common genotypes within subgroups of tumors displaying a "more aggressive phenotype" gene expression profile.
|
21667122 |
2011 |
|
rs1029946
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Here, we investigated the effect on breast cancer survival of germline variation in these genes in 925 Finnish breast cancer patients and further analyzed five single nucleotide polymorphisms (SNPs) in PRKAG2 (rs1029946, rs4726050, rs6464153, rs7789699) and PPP2R2B (rs10477313) for 10-year survival in breast cancer patients, interaction with TP53 R72P and MDM2-SNP309, outcome after specific adjuvant therapy and correlation to tumor characteristics in 4,701 invasive cases from four data sets.
|
23034890 |
2013 |
|
rs1033662
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
There was a suggested association between rs11675434 (TPO gene) and TPO-Ab level, and TPO-Ab-related rs11675434 (TPO), rs3094228 (HCP5), rs1033662 (no registered gene), and rs301806 (RERE) were associated with breast cancer risk.
|
29134650 |
2018 |
|
rs1034794
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
A similar reduced trend for breast cancer-specific mortality was observed for carrying the TERT-14 (rs2853677) T-allele (HR=0.57, 95% CI: 0.39-0.84), while carrying the POT1-18 (rs1034794) T-allele significantly increased breast cancer-specific mortality (HR=1.48, 95% CI: 1.00-2.19).
|
22527105 |
2012 |